Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why Traders Are Piling Into These Five Stocks

Acquisition Amendment Sends Nanosphere Soaring

Nanosphere, Inc. (NASDAQ:NSPH) has surged by 27% after Luminex Corporation (NASDAQ:LMNX) amended its acquisition agreement to acquire Nanosphere. Under the terms of the new deal, the new acquisition price will be $1.70 in cash per share, up from the previous $1.35 per share. The increase was due to an unsolicited third party offer for Nanosphere for $1.50 per share. According to our records, four funds owned $619,000 worth of Nanosphere, Inc. (NASDAQ:NSPH) shares, which accounted for 6.20% of the float on March 31.

Follow Nanosphere Inc (NASDAQ:NSPH)
Trade (NASDAQ:NSPH) Now!

Technical Buying Detected At Cellectar Biosciences Inc

Nano-cap Cellectar Biosciences Inc (NASDAQ:CLRB) is the beneficiary of some technical buying today, as its stock is 32% higher in the morning frame despite there being no fundamental news concerning the company. The only meaningful news last week was Cellectar Biosciences issuing a press release announcing that the company was making progress on its U.S. patent for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles. Two funds out of the 766 funds that Insider Monkey tracks owned $507,000 worth of Cellectar Biosciences’ stock at the end of the first quarter. As with all nano-caps, investors should do their due-diligence before buying.

Relypsa Rallies on Data, Upgrade

Relypsa Inc (NASDAQ:RLYP) is 12% in the green today after the analysts at Morgan Stanley upgraded the stock to ‘Equal Weight’ from ‘Underweight’. Also fueling today’s rally is newly released data that showed Relypsa Inc (NASDAQ:RLYP)’s main drug, Veltassa, may, ‘bind and remove sodium as well as potassium in the gastrointestinal tract’. The data might increase market adoption for Veltassa. A total of 14 funds from our database owned around 1/3 of Relypsa Inc (NASDAQ:RLYP) at the end of March.

Follow Relypsa Inc (NASDAQ:RLYP)
Trade (NASDAQ:RLYP) Now!

Disclosure:None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.